NeuropeptideEditorially reviewed · 28. Mai 2026

DSIP

Also known as Delta Sleep-Inducing Peptide, Delta-Schlaf-induzierendes Peptid

unclassifiedEvidence · preclinical3 studies cited

Structure · schematic

Peptide chain of 9 amino acids · Neuropeptid

Sequence

WAGGDASGE

Schematic representation of the amino acid chain — not a chemical structural formula. Each node represents one amino acid.

Research areas*

Cognition

* Contexts in which the peptide has been scientifically studied — not assured or recommended effects.

§ 1

Mechanism of action

  • DSIP is a nonapeptide (sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in 1977 from the thalamic venous blood of rabbits.
  • Its molecular mechanisms of action remain incompletely understood.
  • Interactions with GABA receptors, a modulating effect on the hypothalamic-pituitary axis and neuroprotective properties via antioxidant pathways have been discussed.
  • In animal experiments, changes in the sleep EEG were observed after intracerebroventricular administration; whether this translates to systemic administration in humans is unclear.
§ 2

Research status

  • Research on DSIP was active in the 1980s and early 1990s and has largely stagnated since.
  • Early human studies investigated intravenous DSIP administration in insomnia and withdrawal syndromes (alcohol, opioids) and observed, in small cohorts, signs of improved sleep quality and reduced withdrawal symptoms.
  • Methodological shortcomings (small sample sizes, lack of placebo control, no replication) preclude valid conclusions.
  • No current clinical development programmes exist; interest in academic research is low.

Evidence level

PreclinicalEarly clinicalEstablished
§ 3

Cited studies

  1. 1984
    Delta sleep-inducing peptide (DSIP): a review
  2. 1985
    DSIP-like material in human blood and cerebrospinal fluid
  3. 1986
    Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients
§ 4

Known risks

  • 01Lack of current safety data — long-term profile in humans unknown
  • 02Possible interactions with central nervous system pathways not sufficiently studied
  • 03Quality control not guaranteed from research-chemical sources
  • 04No established dosing protocols for safe human use
§ 5

Frequently asked questions

What is DSIP?

DSIP is a nonapeptide (sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in 1977 from the thalamic venous blood of rabbits.

What type of peptide is DSIP?

DSIP belongs to the Neuropeptide class.

Is DSIP legal in Germany?

The regulatory status of DSIP in Germany is not clearly classified.

Where can I buy DSIP?

Peptica sells nothing and names no sources. DSIP is "unclassified" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

Is DSIP banned in sport (WADA)?

DSIP is currently not on the WADA Prohibited List.

What are the known risks of DSIP?

Documented risks include: Lack of current safety data — long-term profile in humans unknown; Possible interactions with central nervous system pathways not sufficiently studied. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is DSIP?

The evidence is classified as “preclinical”. 3 studies are cited on this page.

What is the molecular weight of DSIP?

DSIP has a molar mass of about 848.8 Da.

Which peptides are related to DSIP?

Closely related entries: Semax, Selank. A direct side-by-side comparison is available via the compare function.

Related entries

Legal status

Germany

unclassified

Austria

unclassified

Switzerland

unclassified

EU

unclassified

USA

not approved

Canada

not approved

Legal status varies by country and can change. This is not legal advice.

Sources & methodology

  • 3 peer-reviewed studies cited, linked to PubMed where available.
  • Molecular data verified against PubChem and primary literature. PubChem CID 68816
  • Editorial standard: no dosage guidance, no sources, evidence level stated explicitly.

Last editorially reviewed: 28 May 2026

Important notice

This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.

This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.

Anzeige

Reserviert für sorgfältig ausgewählte Partner — Telemedizin, Diagnostik, legale topische Anwendungen.

§ 6

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.